So net-net, we’d expect the exit from California would have a very modest impact on the top line and would have modest accretion to adjusted EBITDA given its historical MLR performance. Moving to the second one, I think your second question, I think your second question was really around year-on-year comparisons for the MLR. You know, really, I think what you’re seeing if you reflect on some of my comments is the membership mix that we have. And in particular, the shift towards more renewing members which as we alluded to will change both the numerator denominator of the MLR calculation. And importantly, it will also flap and the kind of seasonality effect that you’ve seen historically. So, of course, more detailed questions on that, we’re happy to have the team deal with you offline on that.
I think your third question was just on capitation. We don’t specifically disclose that. I think we’ve told you before that they’ve been roughly, 40%-ish of our provider contract are on value based care type arrangements. And I think we’d leave it at that other than to say we continue to believe value based care is a real opportunity as Mark commented in his remarks.
Joshua Raskin: Thank you.
Operator: We’ll take the next question from Michael Ha, Morgan Stanley.
Michael Ha: Hi. Thank you. Just wanted to quickly confirm, are you expecting to grow at least high teens or low 20 membership growth next year, and that includes the Florida market exit. And then my second question is, this one’s for Mark, as we look at +Oscar, and I understand in the past when you’re acting as an advisor, part of your efforts where focused on +Oscar. But looking ahead, now the CEO with the wealth of contact in your Rolodex and Mario laser focused on +Oscar. Curious how you envision the future pipeline developing near term. And I think you mentioned in your prepared remarks, bringing more capability to market does that mean you’re decelerating, modularizing more applications beyond campaign builder? And also sorry. I know five part question, but did you announce the new campaign builder contract today? I wasn’t sure if I heard that correctly. Thank you.
Sid Sankaran: Yeah. So I think — Michael its Sid here, I’ll take the first one then I’ll hand it over to Mark to talk about +Oscar. First off, just restating that was a California market exit that you referenced there. So California, which was, as I said, less than 5% of the overall book. As we execute against the growth objectives that Mark highlighted there, we’ve proven that we can grow in these markets and we continue to target that growth and it’s very realistic for 2024 inclusive of the California decision. But you should expect we’re going to continue to show discipline in the 2024 pricing process around balance and growth and profitability. Because I think as you see in the results this quarter, we feel very positive that the decisions that we’ve been making, to drive the portfolio are really bearing fruit here and showing up in the financials.
So we are pleased about that. Maybe with that, I’ll turn it over to Mark to cover the +Oscar thesis and how he sees that.
Mark T. Bertolini: Sure, and to segue off of Sid’s comments, it’s important that we continue to generate internal generation of capital to support our investments in the business and so we want to exercise pricing discipline. We do want to meet the market or exceed the marketing growth. We believe because of the +Oscar platform that we have a competitive advantage now with an NPS score of 50 when the rest of the industry is averaging around 0. And so we actually, in our distribution model this last year, put that to test in a few markets to see whether or not we could maintain membership with such a high MPS score against the commission race in signing up ACA members. The platform is strong on the front end, very strong on the front end.
